Skin Pharmacology and Physiology · 1999 · 59 citations · 23 references
Life SciencesDermatologyImmunologyAllergyHypersensitivityImmunoregulationAllergic Skin DiseasesContact AllergyContact DermatitisImmunopathology Of SkinMast Cell ActivationSkin SensitizationAllergen-induced Mast Cell ActivationChymase BiologyDermal Hypersensitivity ReactionInduction PhaseMast Cell Degranulation InhibitionMast Cell Degranulation PathwaysMast Cell InhibitorsMast Cell Signal Transduction
The search for effective inhibitors of transdermal drug-induced contact sensitization was directed to dermal mast-cell-degranulating agents (MCDA). Human skin organ cultures were employed to test whether cis-urocanic acid (C-UA) and other potential MCDAs cause mast cell degranulation. These were then tested for their ability to inhibit the induction phase of the contact hypersensitivity reaction (CHR). C-UA at 1 microg/ml significantly depleted mast cell chymase, whereas trans-urocanic acid (T-UA) was relatively ineffective. C-UA, but not T-UA, induced local effects of liberated mast cell TNF-alpha, as detected by E-selectin expression on the microvascular dermal endothelium. C-UA significantly reduced (>70%) the ear swelling response in Balb/c mice, when applied 24 h prior to application of a sensitizing amount of dinitrochlorobenzene (DNCB), and induced a prolonged (>3 weeks) state of immune tolerance (>40%). Similar effects on local immunosuppression of CHR were observed with topical chloroquine and capsaicin, while cromolyn, a mast cell membrane stabilizer, was unable to inhibit DNCB-induced CHR. It is suggested that MCDAs may interfere with downstream events associated with accessory cell function.
23
Laurence J. Walsh, Giorgio Trinchieri, Heidi A. Waldorf et al. · Proceedings of the National Academy of Sciences · 1991 · 623 citations · Full text
E. C. De Fabo, Frances P. Noonan · The Journal of Experimental Medicine · 1983 · 535 citations · Full text
Medicine, Dermatology, Immunology +15